1-3 of 3
Jurgen Rademaker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Clinical Trials & Observations
Alison J. Moskowitz, Paola Ghione, Eric Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah Noor, Patricia Myskowski, Santosha Vardhana, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Alayna Santarosa, Jack Dowd, Obadi Obadi, Lauren Pomerantz, Nancy Yi, Samia Sohail, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Jeeyeon Baik, Mark B. Geyer, Ariela Noy, David Straus, Priyadarshini Kumar, Ahmet Dogan, Travis Hollmann, Esther Drill, Jurgen Rademaker, Heiko Schoder, Giorgio Inghirami, David M. Weinstock, Steven M. Horwitz
Journal: Blood
Blood (2021) 138 (26): 2828–2837.
https://doi.org/10.1182/blood.2021013379
Published: 2021
Includes: Supplemental data
Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas

Neha Mehta-Shah, MD, Alison J. Moskowitz, MD, Matthew A. Lunning, DO, Peggy Lynch, Mark Scheuerman, Veenna Minnal, Natasha Galasso, BA, Anita Kumar, MD, John Gerecitano, MD PhD, Andrew D. Zelenetz, MD PhD, Paul A. Hamlin, MD, Ariela Noy, MD, Matthew J. Matasar, MD, Maria Lia Palomba, MD, Anas Younes, MD, Wendy Schaffer, MD, Ravinder Grewal, MD, Jurgen Rademaker, MD, Craig S. Sauter, MD, Parastoo B. Dahi, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Melissa Pulitzer, MD, Lakeisha Lubin, BS, Laura Tang, Pharm. D, Nivetha Ganesan, BS, Ai Ni, PhD, Steven M. Horwitz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 821.
https://doi.org/10.1182/blood.V130.Suppl_1.821.821
Published: 2017
Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas

Neha Mehta-Shah, MD, Alison J Moskowitz, MD, Matthew Lunning, DO, Peggy Lynch, NP, Mark Scheuerman, Anita Kumar, MD, John F Gerecitano, MD PhD, Andrew D. Zelenetz, MD PhD, Paul A Hamlin, Jr., MD, Ariela Noy, MD PhD, Matthew J. Matasar, MD MS, M. Lia Palomba, MD, Anas Younes, MD, Wendy Schaffer, MD, Ravinder Grewal, MD, Jurgen Rademaker, MD, Craig S Sauter, MD, Parastoo B. Dahi, MD, Patricia Myskowski, MD, Meenal Kheterpal, Ahmet Dogan, MD PhD, Melissa Pulitzer, MD, Laura Tang, Pharm.D, Ai Ni, PhD, Steven M Horwitz, MD
Journal: Blood
Blood (2016) 128 (22): 2991.
https://doi.org/10.1182/blood.V128.22.2991.2991
Published: 2016